| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Preclinical data readout example | Pre-clinical | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Preclinical data readout example | Pre-clinical | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Preclinical data readout example | Pre-clinical | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
GlycoMimetics, Inc.$15.7
-1.02 (-6.1%)
D 39Pipeline Score Overvalued Pharma · Clinical
Market Cap
10.13 M
EPS
-0.46
P/E Ratio
-
Value Trade
171.00 K
0 %
Week
0 %
1 Month
0 %
3 Month
0 %
6 Month
0 %
5 Year
-98.49 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
10.69 K
52 Week Range
null-null
% held by Insiders
22.66 %
% held by Institutions
61.17 %
Enterprise Value
4.52 M
Total Shares
64.53 M
Short %
13.03 %
Float Shares
56.12 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-09 | Uproleselan | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-12-09 | Uproleselan | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-12-09 | Uproleselan | Phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
D39
Pipeline Score $5M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.5x
rNPV / MCap Top 58%
Micro Cap (rank 389 of 923)
Percentile RankGlycoMimetics, Inc. faces pipeline headwinds (39/100), with $2.1B risk-adjusted pipeline value, led by Uproleselan in Multiple Myeloma (Phase 2), across $76B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uproleselan Small molecule | Multiple Myeloma | Phase 2 | NCT04682405 | 19% | $876M | COMPLETED | 51 | - | - | Nov 11, 2022 | - | Dec 15, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
GMI-1687 | treatment of sickle cell disease (SCD) vaso-occlusive crisis (VOC) | Phase 1a | 2024-03-01 | 100% bioavailable in preclinical models following subcutaneous administration Read More | x2022; To the extent that statements contained in this presentation are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of Glyco Read More | |
GMI-1687 | treatment of sickle cell disease (SCD) vaso-occlusive crisis (VOC) | Phase 1a | 2024-03-01 | 100% bioavailable in preclinical models following subcutaneous administration Read More | x2022; To the extent that statements contained in this presentation are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of Glyco Read More | |
GMI-1687 | treatment of sickle cell disease (SCD) vaso-occlusive crisis (VOC) | Phase 1a | 2024-03-01 | 100% bioavailable in preclinical models following subcutaneous administration Read More | x2022; To the extent that statements contained in this presentation are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of Glyco Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GLYC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GLYC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How GLYC ranks across every disease it competes inCompetitive Position is a premium feature
See how GLYC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial